Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,010 across all filing types
Latest filing 2024-04-28 Environmental & Social …
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
2023年度环境、社会及管治（ESG）报告
Environmental & Social Information Classification · 98% confidence The document is titled "康芝药业股份有限公司 2023 年度环境、社会及管治 (ESG）报告" which translates to "Kangzhi Pharmaceutical Co., Ltd. 2023 Environmental, Social and Governance (ESG) Report." It covers detailed information on the company's environmental management, social responsibility, governance structure, and sustainability practices for the year 2023. The content includes extensive data on environmental metrics such as emissions, waste management, energy consumption, and climate risk management. There is no indication that this is an announcement or a brief summary; rather, it is a comprehensive report focused on ESG factors. This matches the definition of Environmental & Social Information (Code: SR), which is a report detailing the company's performance on Environmental, Social, and Governance factors. The document length (15,000 characters) and detailed content confirm it is a full report, not a mere announcement or certification. Therefore, the correct classification is SR with high confidence.
2024-04-28 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 10th meeting of the 6th Board of Directors of 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.) held on April 25, 2024. It includes approvals of various reports such as the 2023 Annual Report, 2023 Financial Statements, Profit Distribution Proposal, Internal Control Self-Evaluation Report, ESG Report, and the 2024 Q1 Report. The document also mentions that these reports will be submitted to the 2023 Annual General Meeting for approval and provides references to where the full reports can be found on the official disclosure website. The document is not the reports themselves but a formal board meeting resolution announcement summarizing decisions and approvals related to the annual report and other corporate governance matters. It is a typical Board/Management Information announcement detailing board meeting resolutions and approvals, not the full annual report or financial statements themselves. Therefore, the correct classification is Board/Management Information (MANG). The document length (8111 characters) and content support this classification, as it is not the full annual report or financial report but a board meeting resolution announcement.
2024-04-28 Chinese
关于调整第六届董事会审计委员会成员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the adjustment of members of the audit committee of the company's sixth board of directors. It details changes in board committee membership, specifically the audit committee, and references compliance with governance regulations. There is no financial data, no report attached or referenced as being published, and no mention of voting results or executive compensation. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2024-04-28 Chinese
董事会战略委员会实施细则 （2024年度修订）
Governance Information Classification · 95% confidence The document is titled as the 'Implementation Rules of the Board Strategic Committee' of 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.). It details the establishment, composition, responsibilities, decision-making procedures, meeting rules, and other governance-related aspects of the Board Strategic Committee. There is no financial data, no mention of fiscal periods, no audit or financial results, no voting results, no legal proceedings, no capital changes, and no investor presentation content. The document is a governance-related internal regulation or procedural guideline for a board committee. This fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 2229 characters, which is relatively short but contains substantive governance content, not just an announcement or notice. Therefore, the appropriate classification is CGR with high confidence.
2024-04-28 Chinese
关于公司2023年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's 2023 profit distribution plan, stating that no dividends or capital increases will be made and explaining the reasons for this decision. It includes opinions from the board of directors, supervisory board, and independent directors, and mentions that the plan will be submitted to the shareholders' meeting for approval. The document is relatively short (1766 characters) and does not contain detailed financial statements or comprehensive financial analysis. It is primarily a formal announcement of a profit distribution proposal and related approvals, not a full financial report or earnings release. Therefore, it fits best into the category of Notice of Dividend Amount (DIV), as it relates to dividend distribution plans and shareholder information about profit allocation.
2024-04-28 Chinese
海通证券关于康芝药业股份有限公司终止部分募集资金投资项目并将剩余募集资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Haitong Securities regarding the termination of certain fundraising investment projects by Kangzhi Pharmaceutical Co., Ltd. and the permanent supplementation of remaining raised funds into working capital. It includes specifics about the original fundraising, project investment status, reasons for termination, and approvals by the board, supervisory committee, independent directors, and the sponsor institution. The document references regulatory guidelines and compliance with Shenzhen Stock Exchange rules. It is a formal verification and opinion report on the use and reallocation of raised funds, not a general financial report or earnings release. This fits the definition of a Capital/Financing Update (CAP) as it deals with fundraising capital usage and changes in investment projects related to raised funds.
2024-04-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.